Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Crescendo Biologics Ltd"'
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 07/24/2023.
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 12/10/2020.
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 05/05/2020.
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 01/15/2020.
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 09/24/2019.
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 07/23/2019.
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 01/03/2019.
Autor:
Crescendo Biologics Ltd
Publikováno v:
Business Wire (English). 04/30/2018.
Autor:
Chocarro L; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain. lchocard@navarra.es., Blanco E; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Fernandez-Rubio L; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Garnica M; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Zuazo M; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Garcia MJ; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Bocanegra A; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Echaide M; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Johnston C; Crescendo Biologics Ltd., Meditrina Building, Babraham Research Campus, Cambridge, CB22 3AT, UK., Edwards CJ; Crescendo Biologics Ltd., Meditrina Building, Babraham Research Campus, Cambridge, CB22 3AT, UK., Legg J; Crescendo Biologics Ltd., Meditrina Building, Babraham Research Campus, Cambridge, CB22 3AT, UK., Pierce AJ; Crescendo Biologics Ltd., Meditrina Building, Babraham Research Campus, Cambridge, CB22 3AT, UK., Arasanz H; Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.; Oncobiona Unit, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Fernandez-Hinojal G; Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Vera R; Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Ausin K; Proteomics Platform, Proteored-ISCIII, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Santamaria E; Proteomics Platform, Proteored-ISCIII, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Fernandez-Irigoyen J; Proteomics Platform, Proteored-ISCIII, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Kochan G; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain., Escors D; OncoImmunology Unit, Navarrabiomed - Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain. descorsm@navarra.es.
Publikováno v:
EMBO molecular medicine [EMBO Mol Med] 2024 Aug; Vol. 16 (8), pp. 1791-1816. Date of Electronic Publication: 2024 Jul 19.
Autor:
Archer S; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Brailey PM; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Song M; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Bartlett PD; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Figueiredo I; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom., Gurel B; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom., Guo C; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom.; Prostate Cancer Targeted Therapies Group, Royal Marsden Hospital, Sutton, United Kingdom., Brucklacher-Waldert V; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Thompson HL; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Akinwale J; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Boyle SE; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Rossant C; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Birkett NR; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Pizzey J; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Maginn M; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Legg J; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Williams R; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Johnston CM; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Bland-Ward P; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., de Bono JS; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom.; Prostate Cancer Targeted Therapies Group, Royal Marsden Hospital, Sutton, United Kingdom., Pierce AJ; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 15; Vol. 30 (8), pp. 1595-1606.